Progress in Medicinal Chemistry

Erscheinungsjahr 2020
ISBN: 978-0-12-821173-1
Verlag: William Andrew Publishing

Buch, Englisch, 260 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 540 g

Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.

Zielgruppe

<p>Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes</p>

Autoren/Hrsg.

Witty, David R.

Cox, Brian

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Organische Chemie

Inhaltsverzeichnis

- Small molecules-Giant leaps for immuno-oncology

Lisa Kötzner, Bayard Huck, Sakshi Garg and Klaus Urbahns

- P2X7 receptor antagonists for the treatment of systemic inflammatory disorders

Christine F. Gelin, Anindya Bhattacharya and Michael A. Letavic

- Discovery and development of ASK1 inhibitors

Reginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas and David Amantini

- An overview of DNA-encoded libraries-A versatile tool for drug discovery

Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen and Nils Jakob Vest Hansen

Über Autor(innen)

Cox, Brian
Professor Brian Cox is at University of Sussex, Brighton, UK

Witty, David R.
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.